Roche's insistence that its much-delayed takeover of Spark Therapeutics Inc. will happen by the end of the year has been boosted by a report from news and legal analysis company Capitol Forum that US Federal Trade Commission staff have cleared the $4.3bn deal.
The report claimed that FTC staff had recommended that the proposed acquisition, announced back in February, be approved without requiring...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?